MetaTrader
  • Märkte
  • Charts & Ideen
  • Algo
  • Nachrichten
  • Store
  • Broker
  • Herunterladen
  • Wirtschaftskalender
  • Handelssignale
  • WebTerminal
  • English English
  • Русский Русский
  • 中文 中文
  • Español Español
  • Português Português
  • 日本語 日本語
  • Deutsch Deutsch
  • 한국어 한국어
  • Français Français
  • Italiano Italiano
Nuvectis Pharma, Inc. Common Stock

NVCT

#3038
Nuvectis Pharma, Inc. Common Stock
8.86
-0.78%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
8.86
8.86
Jahresspanne
5.55
11.52
Tagesänderung
-0.78%
Monatliche Änderung
+0.68%
6 month change
+32.24%
Jahresänderung
+27.85%
Vorheriger Schlusskurs
8.93
Open
8.86
Bid
Ask
Low
8.86
High
8.86
Volumen
17
  1. Märkte
  2. Aktien
  3. Gesundheitswesen
  4. NVCT
Open full chart

Financials

Overview Finanzbericht Statistics Dividends
Quarterly Annual
Value Q3, 24Q4, 24Q1, 25Q2, 25Q3, 25Q4, 25 TTM

Nachrichten

Investing Investing
AZN NVCT
2025.12.17
Nuvectis, NXP900 ile osimertinib kombinasyonunu değerlendiren Faz 1b çalışmasını başlattı
Investing Investing
NVCT
2025.12.17
Nuvectis initiates phase 1b trial combining NXP900 with osimertinib
Investing Investing
NVCT
2025.12.03
H.C. Wainwright, Nuvectis Pharma için Al notunu yineledi
Investing Investing
JNJ NVCT
2025.12.03
Nuvectis Pharma stock rating reiterated at Buy by H.C. Wainwright
Investing Investing
NVCT
2025.11.06
Kaplan, Nuvectis Pharma (NVCT) hisselerinden 64.240 dolar değerinde satın aldı
Investing Investing
NVCT
2025.11.06
Nuvectis Pharma başkanı Bentsur 28.600 dolarlık hisse alımı gerçekleştirdi
Investing Investing
NVCT
2025.11.06
Nuvectis Pharma yöneticisi Sanchez, NVCT hisselerinden 75 bin dolarlık alım yaptı
Investing Investing
NVCT
2025.10.28
H.C. Wainwright, Nuvectis Pharma hissesi için Al tavsiyesini 10 dolar hedefle yineledi
Investing Investing
NVCT
2025.10.28
H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target
Investing Investing
NVCT
2025.09.25
Nuvectis Pharma adds former Intra-Cellular exec to board of directors
Investing Investing
NVCT
2025.08.11
Nuvectis initiates phase 1b program for cancer drug NXP900
The Motley Fool The Motley Fool
NVCT
2025.08.06
Nuvectis (NVCT) Q2 Loss Widens 43%

Märkte

  • Aktien
  • Währungen
  • Kryptowährungen
  • Metalle
  • Rohstoffe

Charts & Ideen

  • Handelsideen
  • Aufbildungsideen
  • Charts

MQL5 Community

  • Market
  • Signale
  • Forum
  • Artikel
  • CodeBase

Nachrichten

  • Aktien
  • Währungen
  • Kryptowährungen
  • Metalle
  • Rohstoffe

Broker

  • Alle Broker
  • Forex
  • Aktien
  • Metalle
MetaTrader 5
MQL5 Channels
Economic Calendar
Haftungsausschluss und Risikohinweis Nutzungsbedingungen Kontakt Rechtliche Hinweise
Copyright 2000-2026, MetaQuotes Ltd